^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Oligodendroglioma

Related cancers:
7d
ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients (clinicaltrials.gov)
P1, N=12, Recruiting, University of Florida | Active, not recruiting --> Recruiting
Enrollment open
8d
Blood‑oxygenation-level-dependent (BOLD) MRI responses to CO2 and O2 inhalation in brain gliomas. (PubMed, Magn Reson Imaging)
Gliomas are associated with abnormal CO2- and O2-reactivity measured with MRI. These dynamic parameters may provide new insights into the vascular pathophysiology in gliomas.
Journal
|
ATRX (ATRX Chromatin Remodeler)
11d
Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype (clinicaltrials.gov)
P=N/A, N=27, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Jan 2025 --> Jan 2026
Trial completion date • Trial primary completion date
|
MSI (Microsatellite instability) • POLE (DNA Polymerase Epsilon) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • POLD1 (DNA Polymerase Delta 1)
|
MSK-IMPACT
|
Keytruda (pembrolizumab)
18d
Studying the Safety, Efficacy, and Pharmacokinetic Characteristics of BNCT in Patients With Recurrent High-grade Gliomas (clinicaltrials.gov)
P1/2, N=7, Terminated, Dawonmedax Co., Ltd. | N=39 --> 7 | Trial completion date: Dec 2024 --> Jun 2024 | Recruiting --> Terminated; The Phase 1 clinical trial was completed, and the study was stopped to initiate a Phase 2 trial with a revised protocol.
Enrollment change • Trial completion date • Trial termination
|
IDH wild-type
18d
Study of Olutasidenib and Temozolomide in HGG (clinicaltrials.gov)
P2, N=60, Recruiting, Rigel Pharmaceuticals | Not yet recruiting --> Recruiting
Enrollment open
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 mutation
|
temozolomide • Rezlidhia (olutasidenib)
18d
ctDNA detection in cerebrospinal fluid and plasma and mutational concordance with the primary tumor in a multicenter prospective study of patients with glioma. (PubMed, Ann Oncol)
CSF is a reliable reservoir for ctDNA analyses in patients with gliomas. ctDNA is detectable in plasma although at a lower rate. Larger, prospective studies should be conducted to refine the potential role of liquid biopsy in this disease.
Journal • Circulating tumor DNA
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • ATRX (ATRX Chromatin Remodeler)
|
TP53 mutation • EGFR mutation • BRAF mutation • PIK3CA mutation • IDH wild-type
18d
Development and validation of a neutrophil extracellular traps-related gene signature for lower-grade gliomas. (PubMed, Comput Biol Med)
LGG individuals in the low-risk category posses a higher likelihood of being sensitive to Carmustine and Vincristine, as indicated by the drug sensitivity analysis. The qRT-PCR experiment and immunohistochemistry images confirmed that the expression of FPR1, PTAFR, SLC11A1 and ICAM1 are higher in low-grade oligodendroglioma. The NETRGs signature and nomogram can accurately and conveniently predict the LGG patients' prognosis, which can facilitate individualized treatment and the improvement of prognosis.
Journal • Gene Signature
|
ICAM1 (Intercellular adhesion molecule 1)
|
vincristine • carmustine
20d
INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas (clinicaltrials.gov)
P1, N=13, Completed, Pediatric Brain Tumor Consortium | Active, not recruiting --> Completed | Trial completion date: Mar 2025 --> Dec 2024
Trial completion • Trial completion date
|
HER-2 (Human epidermal growth factor receptor 2) • CD4 (CD4 Molecule) • ADAM10 (ADAM Metallopeptidase Domain 10)
|
aderbasib (INCB7839)
26d
Trial completion date
26d
A single-arm phase 2 study of abemaciclib in adult patients with recurrent grade 3 oligodendroglioma. (PubMed, Neurooncol Adv)
The efficacy of abemaciclib in recurrent grade 3 oligodendroglioma was inadequate to warrant further evaluation as monotherapy in unselected patients. However, given the objective responses and durable disease control observed in a subset of patients, further studies are warranted to identify subgroups that may benefit.
P2 data • Journal
|
CCND1 (Cyclin D1)
|
Verzenio (abemaciclib)
26d
PRO-GLIO: PROton Versus Photon Therapy in IDH-mutated Diffuse Grade II and III GLIOmas (clinicaltrials.gov)
P=N/A, N=225, Recruiting, Oslo University Hospital | Trial completion date: Dec 2041 --> Dec 2043 | Trial primary completion date: Dec 2025 --> Dec 2027
Trial completion date • Trial primary completion date
30d
Investigating glioma genetics through perfusion MRI: rCBV and rCBF as predictive biomarkers. (PubMed, Magn Reson Imaging)
Integrating perfusion MRI with genetic analysis offers a promising approach to improving the diagnostic and therapeutic landscape for brain tumors, indicating a substantial step toward personalized neuro-oncology. These findings support further validation in larger, multi-institutional studies to solidify their role in clinical practice.
Retrospective data • Journal
|
EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • H3-3A (H3.3 Histone A)
|
EGFR mutation • IDH1 mutation • EGFR amplification • CDKN2A deletion • IDH wild-type
1m
ONC206-001: Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms (clinicaltrials.gov)
P1, N=102, Recruiting, Chimerix | Trial completion date: Feb 2025 --> Dec 2026 | Trial primary completion date: Sep 2024 --> Dec 2025
Trial completion date • Trial primary completion date
|
ONC206
1m
Ivosidenib for the treatment of IDH1-mutant glioma, grades 2-4: Tolerability, predictors of response, and outcomes. (PubMed, Neurooncol Adv)
In this large cohort of IDHm glioma patients, ivosidenib was well tolerated. Our results support the use of IDHi therapy in patients with grade 2 or 3 astrocytoma or oligodendroglioma and highlight limited effectiveness in patients with enhancing disease.
Journal
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 mutation
|
Tibsovo (ivosidenib)
1m
STING: Seizure Treatment in Glioma (clinicaltrials.gov)
P4, N=120, Recruiting, Leiden University Medical Center | Trial completion date: Jan 2028 --> Jul 2028 | Trial primary completion date: Jan 2026 --> Jul 2026
Trial completion date • Trial primary completion date
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 mutation • IDH wild-type
1m
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (clinicaltrials.gov)
P1, N=35, Recruiting, Pediatric Brain Tumor Consortium | Trial completion date: Jun 2028 --> Feb 2030 | Trial primary completion date: Aug 2025 --> Apr 2027
Trial completion date • Trial primary completion date
|
SurVaxM (SVN53-67/M57-KLH peptide vaccine)
1m
MUC1 and MUC4 expression are inversely correlated and trigger immunological response and transport pathways in adult-type diffuse gliomas. (PubMed, Comput Biol Med)
To our knowledge, this is the first retrospective study and in silico analysis demonstrating the relevance and correlation of MUC1 and MUC4 in adult gliomas. These findings elucidate the molecular mechanisms underlying adult-type diffuse glioma progression and highlight MUC1 and MUC4 as potential prognostic markers and therapeutic targets for glioma management.
Journal
|
MUC1 (Mucin 1) • MUC4 (Mucin 4, Cell Surface Associated) • MUC20 (Mucin 20 Cell Surface Associated) • ITGA2 (Integrin Subunit Alpha 2)
1m
ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients (clinicaltrials.gov)
P1, N=12, Active, not recruiting, University of Florida | Recruiting --> Active, not recruiting
Enrollment closed
1m
The α- to γ-enolase switch: The role and regulation of γ-enolase during oligodendrocyte differentiation. (PubMed, Int J Biol Macromol)
Inhibiting cathepsin X similarly changed cell morphology and enhanced oligodendrocyte differentiation. These findings suggest that cathepsin X modulates γ-enolase activity and thereby influences oligodendrocyte differentiation and thus neuronal function.
Journal
|
CTSK (Cathepsin K)
1m
A Pilot Study of Ketogenic Diet and Metformin in Glioblastoma: Feasibility and Metabolic Imaging (clinicaltrials.gov)
P2, N=36, Recruiting, Weill Medical College of Cornell University | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
Trial completion date • Trial primary completion date
|
metformin
1m
Expanded Use of Vorasidenib in Non-Enhancing Recurrent CNS WHO Grade 3 Oligodendroglioma. (PubMed, Biomedicines)
Our case suggests that vorasidenib may impart therapeutic benefits in this setting. This case illustrates the need for further investigation into these less commonly addressed scenarios and treatment strategies that extend beyond current guidelines.
Journal
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
|
Voranigo (vorasidenib)
2ms
Glioma Image-Level and Slide-Level Gene Predictor (GLISP) for Molecular Diagnosis and Predicting Genetic Events of Adult Diffuse Glioma. (PubMed, Bioengineering (Basel))
The accuracy in diagnosing IDH-mutant astrocytoma, oligodendroglioma, and IDH-wild-type glioblastoma was 0.66, surpassing the human pathologist average of 0.62 (0.54-0.67). In conclusion, GLISP is a two-stage AI framework for histology-based prediction of genetic events in adult gliomas, which is helpful in providing essential information for WHO 2021 molecular diagnoses.
Journal
|
EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MGMT (6-O-methylguanine-DNA methyltransferase) • TERT (Telomerase Reverse Transcriptase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • ATRX (ATRX Chromatin Remodeler)
|
TP53 mutation • EGFR mutation • EGFR amplification • CDKN2A deletion • MGMT promoter methylation
2ms
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma (clinicaltrials.gov)
P3, N=540, Active, not recruiting, Eastern Cooperative Oncology Group | Trial primary completion date: Dec 2024 --> Apr 2025
Trial primary completion date
|
temozolomide
2ms
ImproveCodel: A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas). (clinicaltrials.gov)
P3, N=406, Recruiting, University Hospital Heidelberg | Trial completion date: Mar 2029 --> Mar 2031 | Trial primary completion date: Mar 2029 --> Mar 2031
Trial completion date • Trial primary completion date • HEOR
|
temozolomide • vincristine • lomustine • Matulane (procarbazine hydrochloride)
2ms
Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors (clinicaltrials.gov)
P1/2, N=231, Recruiting, Novartis Pharmaceuticals | Trial completion date: Feb 2029 --> Jan 2028 | Trial primary completion date: Feb 2029 --> Oct 2027
Trial completion date • Trial primary completion date
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1)
|
temozolomide • Kisqali (ribociclib) • topotecan
2ms
GPNMB expression differentiates subependymal giant cell astrocytoma from other mimickers. (PubMed, Ann Diagn Pathol)
The results indicated that GPNMB is specifically expressed in all SEGAs, distinguishing it from other morphologically similar tumours. The findings demonstrate specific GPNMB expression in SEGA, underscoring its promise as a diagnostic biomarker.
Journal
|
TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • GPNMB (Glycoprotein Nmb) • TFEB (Transcription Factor EB 2)
2ms
The cortical high-flow sign in oligodendroglioma, IDH-mutant and 1p/19q-codeleted is correlated with histological cortical vascular density. (PubMed, Neuroradiology)
The cortical high-flow sign on ASL, which is more commonly found in ODG IDHm-codel than in diffuse glioma with IDH-wildtype or astrocytoma, is associated with the histological cortical vascular density in patients with ODG IDHm-codel.
Journal
|
CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
2ms
Journal
|
CD8 (cluster of differentiation 8) • NCOA4 (Nuclear Receptor Coactivator 4)
2ms
Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults with Brain Tumors (clinicaltrials.gov)
P=N/A, N=300, Recruiting, Pediatric Brain Tumor Consortium | Active, not recruiting --> Recruiting
Enrollment open • Liquid biopsy
2ms
Study of How Safe and Effective Tarlatamab is in Brain Cancers (clinicaltrials.gov)
P2, N=44, Not yet recruiting, University Health Network, Toronto
New P2 trial
|
Imdelltra (tarlatamab-dlle)
2ms
TERTp Mutation and its Prognostic Value in Glioma Patients Under the 2021 WHO Classification: A Real-World Study. (PubMed, Cancer Med)
In the IDH-mutant subgroup, it tended to co-occur with CIC and FUBP1 alterations, while being mutually exclusive with ATRX and TP53 alterations. These correlations may further refine prognostic predictions.
Journal • Real-world evidence
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • TERT (Telomerase Reverse Transcriptase) • ATRX (ATRX Chromatin Remodeler) • FUBP1 (Far Upstream Element Binding Protein 1)
|
KRAS mutation • EGFR mutation • MET mutation • TERT mutation
2ms
Development and Validation of a Prognostic Molecular Phenotype and Clinical Characterization in Grade III Diffuse Gliomas Treatment with Radio-Chemotherapy. (PubMed, Ther Clin Risk Manag)
The calibration curve showed that the established nomogram could well predict the survival based on these covariates. The AA-G3 with IDH-1 wildtype, MGMT unmethylation or 1p/19q non-codeletion patients was resistant to radiotherapy and chemotherapy, has a poor prognosis and needs a more active treatment.
Journal
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • MGMT (6-O-methylguanine-DNA methyltransferase)
|
IDH1 mutation • MGMT unmethylation
2ms
Journal
|
TERT (Telomerase Reverse Transcriptase)
|
TERT mutation • TERT promoter mutation
2ms
Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma (clinicaltrials.gov)
P1, N=60, Active, not recruiting, Case Comprehensive Cancer Center | Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
Trial completion date • Trial primary completion date
|
temozolomide • Jakafi (ruxolitinib)
2ms
Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma (clinicaltrials.gov)
P2, N=2, Terminated, Wake Forest University Health Sciences | N=36 --> 2 | Suspended --> Terminated; Axsome has conducted a review of the ongoing IST program and are unable to continue supporting this study
Enrollment change • Trial termination • HEOR
|
MGMT (6-O-methylguanine-DNA methyltransferase)
2ms
The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma. (PubMed, Neuro Oncol)
In this review, we address the role of vorasidenib in the treatment of IDH-mutant gliomas, providing a roadmap for its incorporation into daily practice. We discuss ongoing clinical trials with vorasidenib and other IDH inhibitors, as single-agent or in combination with other therapies, as well as current challenges and future directions.
Journal
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
|
IDH1 mutation
|
Voranigo (vorasidenib)
3ms
Sarcomatous transformation of IDH-mutant astrocytoma matching to methylation class oligosarcoma following embolization, a case report. (PubMed, Acta Neuropathol Commun)
Both lack the defining 1p/19q co-deletion or copy-neutral heterozygosity of an oligodendroglioma and oligosarcoma. The findings in this case report both contribute to the apparent heterogeneity of the novel MC oligosarcoma and describe a second reported mesenchymal transformation of an IDH-mutant astrocytoma.
Journal
|
TP53 (Tumor protein P53)
3ms
The landscape of primary mismatch repair deficient gliomas in children, adolescents, and young adults: a multi-cohort study. (PubMed, Lancet Oncol)
Primary MMRD is more common than previously reported in gliomas in children, adolescents, and young adults, is enriched in specific molecular subgroups, and is associated with poor outcomes. Accurate detection, genetic testing, early diagnosis through surveillance, and implementation of immunotherapy might improve survival for these patients.
Journal • Mismatch repair • IO biomarker
|
TP53 (Tumor protein P53)
|
BRAF V600E • MSI-H/dMMR • BRAF V600
3ms
Oligoastrocytoma: The Vanishing Entity With True Dual Genotype, a Report, its Molecular Profiles and Review of Literature. (PubMed, Int J Surg Pathol)
TERT mutation was present in the oligodendroglioma component, whereas it was absent in the astrocytoma component. Although rare, gliomas harboring both oligodendroglioma and astrocytoma components in a single tumor exist and show genetically distinct areas.
Review • Journal
|
TP53 (Tumor protein P53) • TERT (Telomerase Reverse Transcriptase) • ATRX (ATRX Chromatin Remodeler)
|
TP53 mutation • ATRX mutation • TERT mutation • TP53 expression
3ms
Pharmacological Blockade of Group II Metabotropic Glutamate Receptors Reduces the Incidence of Brain Tumors Induced by Prenatal Exposure to N-ethyl-N-nitrosourea in Rats. (PubMed, Curr Neuropharmacol)
Tumors in both groups of rats showed a moderate/high expression of the astrocyte marker, GFAP, and the oligodendrocyte marker, OLIG-2, and a low expression of the proliferation marker, Ki-67. However, tumors of the ENU + LY341495 group showed a reduced density of Iba-1+ cells, suggesting a lower extent of neuroinflammation in the tumor microenvironment. These findings strengthen the hypothesis that mGlu3 receptors are candidate drug targets for the treatment of malignant gliomas.
Preclinical • Journal
|
GFAP (Glial Fibrillary Acidic Protein)
3ms
A Drug-drug Interaction Study of Avapritinib and Midazolam (clinicaltrials.gov)
P1, N=10, Completed, Blueprint Medicines Corporation | Active, not recruiting --> Completed | Trial completion date: Sep 2025 --> May 2024
Trial completion • Trial completion date • Stroma • Metastases
|
KIT (KIT proto-oncogene, receptor tyrosine kinase)
|
Ayvakit (avapritinib) • midazolam hydrochloride
3ms
Are PDFGRA Dinucleotide Alterations Definitional for Myxoid Glioneuronal Tumor? Report of PDFRA p. K385L Mutation in a Neonatal High-Grade Glioma. (PubMed, Pediatr Dev Pathol)
In summary, we report the occurrence of PDGFRA hotspot mutation in a neonatal high-grade glioma without distinct features of MGNT, demonstrating that this genetic alteration is not specific to MGNT. We recommend caution in classifying a tumor as MGNT solely by the presence of PDGFRA alteration.
Journal
|
PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
|
PDGFRA mutation